Cancer drug side effect under the microscope: how common is high ammonia?
NCT ID NCT06600659
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks how often patients being treated with recombinant Erwinia asparaginase (Rylaze) for blood cancers develop high ammonia levels, a condition called hyperammonemia. Researchers will measure ammonia in the blood of 10 children and teens during their first two treatment cycles. The goal is to better understand who is at risk and how common this side effect is.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBKASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- A simple blood draw could spare kids with leukemia from painful bone marrow tests
- A virtual pharmacy visit may ease opioid fears for cancer patients